Recent News

• 04.24.2025 - Insmed Announces Redemption of all $569.5 Million of Remaining Outstanding 0.75% Convertible Senior Notes Due 2028
• 04.23.2025 - New England Journal of Medicine Publishes Positive Results from Insmed's Pivotal Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis
• 04.23.2025 - Insmed to Host First-Quarter 2025 Financial Results Conference Call on Thursday, May 8, 2025
• 03.25.2025 - Insmed to Present 11 Abstracts from Across Its Respiratory Portfolio at the American Thoracic Society 2025 International Conference
• 03.10.2025 - Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Recent Filings

• 04.24.2025 - 8-K/A Current report
• 04.24.2025 - 8-K Current report
• 04.24.2025 - EX-99.1 EX-99.1
• 04.17.2025 - 8-K Current report
• 04.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.15.2025 - 144 Report of proposed sale of securities
• 04.04.2025 - DEF 14A Other definitive proxy statements
• 04.04.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.04.2025 - ARS Annual Report to Security Holders
• 04.03.2025 - 4 Statement of changes in beneficial ownership of securities